

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)



(10) International Publication Number
WO 2023/164537 A1

(51) International Patent Classification:

A61K 31/40 (2006.01) *A61K 31/341* (2006.01)

A61K 31/395 (2006.01) *A61K 31/33* (2006.01)

(21) International Application Number:

PCT/US2023/063113

(22) International Filing Date:

23 February 2023 (23.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/313,212 23 February 2022 (23.02.2022) US

(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.**
[US/US]; Biohaven Therapeutics Ltd., 215 Church Street,
New Haven, Connecticut 06510 (US).

(72) Inventors: **RESNICK, Lynn**; Biohaven Therapeutics Ltd.,
215 Church Street, New Haven, Connecticut 06510 (US).
HALE, James S.; Biohaven Therapeutics Ltd., 215 Church
Street, New Haven, Connecticut 06510 (US). **FLENTGE,**
Charles A.; Biohaven Therapeutics Ltd., 215 Church
Street, New Haven, Connecticut 06510 (US). **PATHI, Su-**
man; Biohaven Therapeutics Ltd., 215 Church Street, New
Haven, Connecticut 06510 (US). **AMAYE, Isis J.**; Bio-
haven Therapeutics Ltd., 215 Church Street, New Haven,
Connecticut 06510 (US). **MARESKA, David A.**; Biohaven
Therapeutics Ltd., 215 Church Street, New Haven, Con-
necticut 06510 (US).

(74) Agent: **ZUEV, Dmitry**; Biohaven Therapeutics Ltd., 215
Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS

(57) Abstract: Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

WO 2023/164537 A1